This report is designed for companies and decision-makers seeking actionable insights on market size, growth, trends, and competitive strategies to drive expansion and success in the Cosentyx Drug industry.
What is the anticipated market size of the cosentyx drug industry over the next few years?
The cosentyx drug market size has grown strongly in recent years. It will grow from $5,195.11 million in 2024 to $5,683.20 million in 2025 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to FDA approval and early market entry, clinical efficacy and safety profile, shift toward biologics, real-world data, and long-term benefits, and global regulatory approvals.
The cosentyx drug market size is expected to see strong growth in the next few years. It will grow to $8,030.80 million in 2029 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to the increasing prevalence of autoimmune diseases, expansion of approved indications, advancements in biologic therapies, favorable reimbursement policies, and strong clinical outcomes. Major trends in the forecast period include expanding applications for autoimmune diseases, shifting toward personalized medicine, and the dominance of subcutaneous administration and R&D in new therapeutic areas.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19891&type=smp
What emerging drivers are expected to shape the future of the cosentyx drug market?
The rising prevalence of autoimmune diseases is expected to propel the growth of cosentyx market going forward. Autoimmune diseases refer to disorders characterized by the immune system mistakenly attacking the body’s healthy cells and tissues. The rising prevalence of autoimmune diseases is attributed to genetic predisposition, environmental factors (such as infections and pollutants), and lifestyle changes, including increased stress and dietary shifts. Cosentyx (secukinumab) helps autoimmune disease patients by targeting and inhibiting interleukin-17A, a key cytokine involved in the inflammatory process, thereby reducing symptoms, improving quality of life, and managing conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis effectively. For instance, in July 2023, according to the data from Public Health Scotland, a Scotland-based national organization, newly diagnosed patients with multiple sclerosis (MS) increased to 87.2%, up from 85.7%, with 491 new cases reported, bringing the total to 6,359 in 2022. Therefore, the rising prevalence of autoimmune diseases drives the cosentyx market.
Rising Healthcare Expenditure Expected To Enhance Cosentyx Drug
Rising healthcare expenditure is expected to propel the growth of the cosentyx market going forward. Healthcare expenditure refers to the total amount spent on healthcare goods and services, including personal health care, preventive services, and public health activities, aimed at improving health outcomes within a specific period. The rising healthcare expenditure is due to an aging population, chronic diseases, advanced medical technology, high drug prices, inefficient payment models, and increased demand for services. Healthcare expenditure for Cosentyx is primarily directed toward managing moderate to severe psoriasis, psoriatic arthritis, and ankylosing spondylitis, improving patient outcomes through targeted biologic therapy. For instance, in May 2024, according to a report published by Office For National Statistics, a UK-based government agency, total healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, compared to a growth rate of 0.9% in 2022. Additionally, total long-term health and social care expenditure increased by 2.8% in real terms in 2022. Therefore, the rising healthcare expenditure is driving the cosentyx market.
What emerging segments are shaping the future landscape of the cosentyx drug industry?
The cosentyx drug market covered in this report is segmented –
1) By Indication: Hidradenitis suppurativa; Psoriatic arthritis; Ankylosing spondylitis; Plaque Psoriasis
2) By Route Of Administration: Subcutaneous injection; Intravenous infusion
3) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/cosentyx-drug-global-market-report
What are the top market trends driving innovation in the cosentyx drug industry?
The key trend in the cosentyx drug market is focusing on developing advanced therapies such as biological treatment options to address unmet medical needs, enhance treatment efficacy, and provide targeted therapies for managing chronic autoimmune conditions, thereby strengthening their market position and catering to a growing patient population. Biologic treatments are advanced therapies derived from living organisms or their cells that specifically target components of the immune system, such as interleukin-17A, to modulate inflammatory responses and effectively treat autoimmune conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. For instance, in October 2023, Novartis AG, A Switzerland-based pharmaceutical company, received FDA approval for Cosentyx (secukinumab) as the first new biologic treatment option for moderate to severe hidradenitis suppurativa (HS) in nearly a decade. This approval marks a significant advancement in the treatment landscape for HS, a chronic and often debilitating skin condition characterized by painful lumps that can lead to scarring and psychological distress.
How are key players in the cosentyx drug market strengthening their market position?
Major companies operating in the cosentyx drug market include Novartis AG
Which geographic areas are contributing significantly to the growth of the cosentyx drug sector?
North America was the largest region in the cosentyx drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cosentyx drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Cosentyx Drug Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19891
Need Customized Data On Cosentyx Drug Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/customise?id=19891&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
